Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 25, 2017. The report details positive interim results from the DAWNING study, a Phase IIIb clinical trial conducted by ViiV Healthcare, a global specialist HIV company majority-owned by GSK. The study evaluates second-line HIV treatment options in resource-limited settings.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial outcomes and product safety information.
Material Changes and Clinical Results
The primary material update concerns the DAWNING study comparing dolutegravir (DTG) against lopinavir/ritonavir (LPV/RTV) for second-line HIV treatment:
- Study Modification: The Independent Data Monitoring Committee (IDMC) recommended discontinuing the LPV/RTV treatment arm due to significant efficacy differences favoring dolutegravir. Patients in the control arm were offered the opportunity to switch to dolutegravir-based regimens.
- Efficacy Data: At the 24-week interim analysis, the dolutegravir arm achieved an 82% response rate (plasma HIV-1 RNA <50 copies/mL), compared to 69% for the lopinavir/ritonavir arm (p<0.001).
- Resistance: No subjects in the dolutegravir arm developed treatment failure with integrase or nucleoside resistance.
- Safety: Safety data for dolutegravir at week 24 was consistent with previous studies.
Outlook, Risks, and Management Commentary
Management Commentary: John C. Pottage, Jr., MD, Chief Scientific and Medical Officer at ViiV Healthcare, stated that the results reaffirm dolutegravir's position at the core of HIV care and may guide second-line treatment decisions in resource-limited settings. The company is working to provide dolutegravir to patients in the control arm and anticipates sharing 48-week results in the future.
Risks and Contingencies: The filing includes standard safety warnings for TIVICAY (dolutegravir), including:
- Hypersensitivity: Reactions characterized by rash and organ dysfunction (including liver injury) have been reported in <1% of subjects.
- Hepatitis: Patients with Hepatitis B or C co-infection may be at increased risk for transaminase elevations.
- Drug Interactions: Coadministration with certain inducers of UGT1A and/or CYP3A may reduce plasma concentrations, requiring dose adjustments.
- Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their 2016 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the impact of the DAWNING study results on future sales projections for TIVICAY (dolutegravir) in emerging markets.
- Confirm the timeline for the release of the full 48-week study data.
- Review the full Prescribing Information for TIVICAY regarding specific drug interactions and contraindications.
- Check subsequent filings for any financial updates related to ViiV Healthcare's performance, as this specific filing contains no financial figures.